Meeting
2022 ASCO Annual Meeting
Real-world clinical outcomes in patients with local/regional HER2-low breast cancer: An NCDB analysis.
Authors
Changchuan Jiang
Roswell Park Cancer Center, Buffalo, NY
Changchuan Jiang , Stuthi Perimbeti , Lei Deng , Qian Wang , Shipra Gandhi , Charles L. Shapiro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 558)
DOI
10.1200/JCO.2022.40.16_suppl.558
Abstract #
558
Poster Bd #
330
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
First Author: Seth Andrew Wander
Poster
2022 ASCO Annual Meeting
Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort.
First Author: Marcela Carausu
Poster
2021 Genitourinary Cancers Symposium
Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.
First Author: Daniel M. Geynisman
Poster
2021 Genitourinary Cancers Symposium
Retrospective cohort analysis of real-world clinical outcomes in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) treated with novel androgen receptor pathway inhibitors (ARPI).
First Author: Richard Gagnon